KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsCash from RestructuringChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Resmed (RMD) Capital Expenditures (2016 - 2025)

Resmed (RMD) has disclosed Capital Expenditures for 17 consecutive years, with $28.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Capital Expenditures rose 38.24% year-over-year to $28.5 million, compared with a TTM value of $122.9 million through Dec 2025, up 45.33%, and an annual FY2025 reading of $89.9 million, down 9.65% over the prior year.
  • Capital Expenditures was $28.5 million for Q4 2025 at Resmed, down from $43.0 million in the prior quarter.
  • Across five years, Capital Expenditures topped out at $48.4 million in Q1 2022 and bottomed at $17.8 million in Q3 2024.
  • Average Capital Expenditures over 5 years is $28.5 million, with a median of $28.2 million recorded in 2021.
  • The sharpest move saw Capital Expenditures tumbled 40.6% in 2024, then surged 140.84% in 2025.
  • Year by year, Capital Expenditures stood at $30.4 million in 2021, then dropped by 10.05% to $27.4 million in 2022, then fell by 14.61% to $23.4 million in 2023, then fell by 11.6% to $20.6 million in 2024, then skyrocketed by 38.24% to $28.5 million in 2025.
  • Business Quant data shows Capital Expenditures for RMD at $28.5 million in Q4 2025, $43.0 million in Q3 2025, and $30.6 million in Q2 2025.